A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects With Chronic Hepatitis B Virus Infection (B-SUPREME)

This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.

开始日期2025-07-15

申办/合作机构

ALIGOS THERAPEUTICS INC

NCT06672900

/ Active, not recruiting临床1期

A Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of Multiple Doses of ALG-000184.

This Phase 1 study consists of two parts, all conducted in healthy volunteers (HVs).
In Part 1, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Itraconazole; participants will be assigned to receive multiple doses of ALG-000184 and Itraconazole over a two week period.
In Part 2, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Carbamazepine; participants will be assigned to receive multiple doses of ALG-000184 and ascending doses of Carbamazepine over an 18 day period.
The 2 parts may be conducted in parallel.

开始日期2025-01-09

申办/合作机构

ALIGOS THERAPEUTICS INC

CTR20211304

/ Recruiting临床1期

一项随机双盲、安慰剂对照、口服ALG-000184的首次人体Ⅰ期研究以评估健康志愿者单次给药剂量递增（第1部分）和多次给药剂量递增（第2部分）以及慢性乙型肝炎受试者多次给药（第3部分）的安全性、耐受性、药代动力学和药效学。

评估口服ALG-000184在健康志愿者单次给药剂量递增（第1部分）和多次给药剂量递增（第2部分）以及慢性乙型肝炎受试者多次给药（第3部分）的安全性、耐受性、药代动力学和药效学。

开始日期2021-07-26

申办/合作机构

缔脉生物医药科技（上海）有限公司

[+3]

100 项与 Pevifoscorvir sodium 相关的临床结果

登录后查看更多信息

100 项与 Pevifoscorvir sodium 相关的转化医学

登录后查看更多信息

100 项与 Pevifoscorvir sodium 相关的专利（医药）

登录后查看更多信息

项与 Pevifoscorvir sodium 相关的文献（医药）

2024-12-12·JOURNAL OF MEDICINAL CHEMISTRY

The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075

Article

作者: Zhang, Yafeng ; Smith, David B. ; Chanda, Sushmita ; Geng, Xiu ; Deval, Jerome ; Bassit, Leda ; Beigelman, Leonid N. ; Debing, Yannick ; Raboisson, Pierre ; Vanrusselt, Hannah ; Sanchez, Abel Acosta ; Serebryany, Vladimir ; Welch, Michael ; Hu, Haiyang ; Symons, Julian A. ; Liu, Jyanwei ; Jekle, Andreas ; Gupta, Kusum ; Stoycheva, Antitsa D. ; Tan, Hua ; Kum, Dieudonné Buh ; Williams, Caroline ; Kang, Hyunsoon ; Amblard, Franck ; Hu, Xiaojuan ; Misner, Dinah L. ; Zhang, Liangliang ; McGowan, David C. ; Liu, Cheng ; Blatt, Lawrence M. ; Chou, Lang ; Chen, Xiaoyuan ; Vendeville, Sandrine ; Zhang, Qingling ; Schinazi, Raymond F.

Chronic hepatitis B (CHB) represents a significant unmet medical need with few options beyond lifelong treatment with nucleoside analogues, which rarely leads to a functional cure. Novel agents that reduce levels of HBV DNA, RNA and other viral antigens could lead to better treatment outcomes. The capsid assembly modulator (CAM) class of compounds represents an important modality for chronic suppression and to improve functional cure rates, either alone or in combination. GLP-26 is a potent CAM, which in this work was optimized for potency, safety, and other drug-like properties leading to ALG-001075. ALG-001075 was further advanced through clinical development as the highly soluble prodrug ALG-000184. ALG-000184 is currently being explored in multiple clinical trials in HBV-infected subjects where unprecedented reductions in HBV DNA, RNA and other viral antigens have been observed, making ALG-000184 a promising candidate to become a cornerstone for future chronic suppressive and combination treatment regimens for CHB.

项与 Pevifoscorvir sodium 相关的新闻（医药）

2025-10-16

·investor.aligos.com

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the United States Adopted Names (USAN) Council has adopted pevifoscorvir sodium as the nonproprietary (generic) name for ALG-000184, under investigation for the treatment of chronic hepatitis B virus (HBV) infection. The USAN, consisting of members from the Food and Drug Administration (FDA), American Medical Association (AMA), United States Pharmacopeia (USP) and the American Pharmacists Association (APhA), is responsible for developing simple, informative and unique nonproprietary (generic) drug names. “The adoption of pevifoscorvir sodium, or pevy, marks the first generic name for a compound at Aligos,” stated Lawrence Blatt, PhD, MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “As we continue to progress our Phase 2 B-Supreme study, we look forward to adopting this new name. This milestone showcases our continued innovation in the liver and viral disease space and reinforces our commitment to improving patient outcomes.” Generic drug names like pevifoscorvir sodium ensure consistent identification. Standardized naming also supports international recognition and transparency across markets. About pevifoscorvir sodium Pevifoscorvir sodium (formerly known as ALG-000184) was derived from initial IP licensed from the laboratory of Dr. Raymond Schinazi at Emory University, which was further optimized by Aligos. Pevifoscorvir sodium is a potent potential best/first-in-class oral small molecule capsid assembly modulator (CAM-E) being developed for chronic hepatitis B virus (HBV) infection. Phase 1 studies have demonstrated after single and multiple daily doses that pevifoscorvir sodium was well-tolerated by study participants, with no safety signals observed, and demonstrated linear PK and excellent antiviral activity. In longer term Phase 1 studies, pevifoscorvir sodium 300mg QD x ≤96 weeks ± entecavir (ETV) and pevifoscorvir sodium monotherapy have demonstrated sustained reductions in HBV DNA, RNA, HBsAg, HBeAg, and HBcrAg. Pevifoscorvir sodium has a regulatory path, as acknowledged by the FDA, EMA, and NMPA (China), for subsequent studies utilizing the chronic suppressive pathway. Phase 1 96-week dosing of pevifoscorvir sodium has been completed with the final and post-treatment follow up data expected at the American Association for the Study of Liver Disease’s The Liver Meeting® in 2025. The Phase 2 B-SUPREME study initiated in August 2025, with interim data projected in 2026, and topline data anticipated in 2027. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. For more information, please visit www.aligos.com or follow us on LinkedIn or X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Investor Contact Aligos Therapeutics, Inc. Jordyn Tarazi Vice President, Investor Relations & Corporate Communications +1 (650) 910-0427 jtarazi@aligos.com Media Contact Inizio Evoke Jake Robison Vice President Jake.Robison@inizioevoke.com

临床结果临床1期临床2期

2025-10-07

·GlobeNewswire-Health Care

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight presentations, including one oral presentation, at The Liver Meeting® 2025, being held November 7 – 11, 2025 in Washington, D.C. The abstracts released today can be found on the AASLD website at https://www.aasld.org/the-liver-meeting. Details on the abstracts are as follows: ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection Publication #: 0198Type: Oral PresentationTitle: Oral Once -Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator Demonstrates potent suppression of HBV DNA in Treatment-Naive or Currently-not-treated Subjects with Chronic HBVPresenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong KongDate/Time: November 9, 2025 at 5:00pm – 6:30pm ETSession: Next-generation HBV Therapeutics: Emerging Therapies and Search for Functional Cure Publication #: 1208Type: Poster PresentationTitle: Sustained Reduction of HBV Antigen Levels During the 8-Week Follow-up Period in Treatment Naïve (TN) or Currently-Not-Treated (CNT) HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection After 96-Week 300 mg ALG-000184Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong KongDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Publication #: 1251Type: Poster PresentationTitle: Capsid Assembly Modulator ALG-001075 Prevents cccDNA Formation and HBV DNA Integration In VitroPresenter: Jordi VerheyenDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Publication #: 1338Type: Poster PresentationTitle: Capsid Assembly Modulator ALG-001075 Binds and Directly Targets HBeAgPresenter: Jordi VerheyenDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Preclinical Publication #: 1248Type: Poster PresentationTitle: Differentiation of HBV capsid assembly modulators based on stabilization of core protein oligomerization and residence timePresenter: Cheng Liu, PhDDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Publication #: 1330Type: Poster PresentationTitle: CAM-E and CAM-A Compounds Differentially Affect Phosphorylated and Non-Phosphorylated Hepatitis B Core Protein In VitroPresenter: Rene Geissler, PhD, Abbott Diagnostics DivisionDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Publication #: 1155Type: Poster PresentationTitle: Lead Optimization and Selection of a Potential Best-in-Class HBV ASOPresenter: Jin Hong, PhDDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Publication #: 1103Type: Poster PresentationTitle: Two Pre-clinical Short Interfering RNA Molecules Targeting Human HSD17beta13 for the Treatment of Metabolic Dysfunction-Associated SteatohepatitisPresenter: Jieun Song, PhDDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: MASLD/MASH - Experimental: Basic ("1001-1117") About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. For more information, please visit www.aligos.com or follow us on LinkedIn or X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Investor ContactAligos Therapeutics, Inc.Jordyn TaraziVice President, Investor Relations & Corporate Communications+1 (650) 910-0427jtarazi@aligos.com Media ContactInizio EvokeJake RobisonVice PresidentJake.Robison@inizioevoke.com

临床1期siRNA

2025-10-07

·investor.aligos.com

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight presentations, including one oral presentation, at The Liver Meeting® 2025, being held November 7 – 11, 2025 in Washington, D.C. The abstracts released today can be found on the AASLD website at https://www.aasld.org/the-liver-meeting. Details on the abstracts are as follows: ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection Publication #: 0198Type: Oral PresentationTitle: Oral Once -Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator Demonstrates potent suppression of HBV DNA in Treatment-Naive or Currently-not-treated Subjects with Chronic HBVPresenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong KongDate/Time: November 9, 2025 at 5:00pm – 6:30pm ETSession: Next-generation HBV Therapeutics: Emerging Therapies and Search for Functional Cure Publication #: 1208Type: Poster PresentationTitle: Sustained Reduction of HBV Antigen Levels During the 8-Week Follow-up Period in Treatment Naïve (TN) or Currently-Not-Treated (CNT) HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection After 96-Week 300 mg ALG-000184Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong KongDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Publication #: 1251Type: Poster PresentationTitle: Capsid Assembly Modulator ALG-001075 Prevents cccDNA Formation and HBV DNA Integration In VitroPresenter: Jordi VerheyenDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Publication #: 1338Type: Poster PresentationTitle: Capsid Assembly Modulator ALG-001075 Binds and Directly Targets HBeAgPresenter: Jordi VerheyenDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Preclinical Publication #: 1248Type: Poster PresentationTitle: Differentiation of HBV capsid assembly modulators based on stabilization of core protein oligomerization and residence timePresenter: Cheng Liu, PhDDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Publication #: 1330Type: Poster PresentationTitle: CAM-E and CAM-A Compounds Differentially Affect Phosphorylated and Non-Phosphorylated Hepatitis B Core Protein In VitroPresenter: Rene Geissler, PhD, Abbott Diagnostics DivisionDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Publication #: 1155Type: Poster PresentationTitle: Lead Optimization and Selection of a Potential Best-in-Class HBV ASOPresenter: Jin Hong, PhDDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: Hepatitis B (“1118-1367”) Publication #: 1103Type: Poster PresentationTitle: Two Pre-clinical Short Interfering RNA Molecules Targeting Human HSD17beta13 for the Treatment of Metabolic Dysfunction-Associated SteatohepatitisPresenter: Jieun Song, PhDDate/Time: November 7, 2025 at 8:00am – 5:00pm ETSession: MASLD/MASH - Experimental: Basic ("1001-1117") About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. For more information, please visit www.aligos.com or follow us on LinkedIn or X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Investor ContactAligos Therapeutics, Inc.Jordyn TaraziVice President, Investor Relations & Corporate Communications+1 (650) 910-0427jtarazi@aligos.com Media ContactInizio EvokeJake RobisonVice PresidentJake.Robison@inizioevoke.com

siRNA

100 项与 Pevifoscorvir sodium 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性乙型肝炎	临床2期	美国	ALIGOS THERAPEUTICS INC	2025-07-15
慢性乙型肝炎	临床2期	中国	ALIGOS THERAPEUTICS INC	2025-07-15
慢性乙型肝炎	临床2期	保加利亚	ALIGOS THERAPEUTICS INC	2025-07-15
慢性乙型肝炎	临床2期	加拿大	ALIGOS THERAPEUTICS INC	2025-07-15
慢性乙型肝炎	临床2期	法国	ALIGOS THERAPEUTICS INC	2025-07-15
慢性乙型肝炎	临床2期	中国香港	ALIGOS THERAPEUTICS INC	2025-07-15
慢性乙型肝炎	临床2期	意大利	ALIGOS THERAPEUTICS INC	2025-07-15
慢性乙型肝炎	临床2期	摩尔多瓦	ALIGOS THERAPEUTICS INC	2025-07-15
慢性乙型肝炎	临床2期	新西兰	ALIGOS THERAPEUTICS INC	2025-07-15
慢性乙型肝炎	临床2期	罗马尼亚	ALIGOS THERAPEUTICS INC	2025-07-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04536337 (GlobeNewswire) 人工标引	临床1期	慢性乙型肝炎	11	ALG-000184ALG-000184 300 mg monotherapy (HBeAg+)	餘齋齋遞繭繭構廠蓋範(窪齋憲壓願構願願壓艱) = 鑰網艱願鬱蓋選願憲憲製衊網選夢憲窪齋窪鏇 (顧夢願蓋廠膚遞選鏇淵 ) 更多	积极	2025-03-26
				ALG-000184 300 mg monotherapy (HBeAg-)	餘齋齋遞繭繭構廠蓋範(廠窪窪糧鬱鹽夢築簾範) = 網願醖積蓋淵廠窪鑰獵蓋獵鬱蓋網窪築簾遞鑰 (蓋選範繭簾蓋襯觸鬱製 )
NCT04536337 (ALG-000184-201, EASL2024) 人工标引	临床1期	慢性乙型肝炎 \| 完全性房室传导阻滞	11	ALG-000184 300 mg	選醖觸遞獵淵願鹹艱膚(積選鏇願襯繭鹹顧壓憲) = 艱鹹網壓觸醖築繭壓築網獵鬱窪範鬱築願積獵 (膚夢醖齋艱衊醖鬱壓鑰 ) 更多	积极	2024-06-01
NCT04536337 (ALG-000184-201, EASL2024) 人工标引	临床1期	慢性乙型肝炎	22	ALG-000184 + ETV	餘衊鹹窪夢願齋鬱壓膚(顧構糧鏇觸鹽壓鹽壓鏇) = In a multiple regression model, baseline HBsAg (< or ≥4 log10 IU/ ml) and steady state plasma ALG-001075 exposure (AUC or Ctrough) statistically significantly predicted change from baseline in HBsAg at week 24 (p < 0.00018, R2 = 0.65). 糧願憲築窪糧餘糧築糧 (觸遞觸獵範衊顧醖繭願 ) 更多	积极	2024-06-01
				ALG-000184
NCT04536337 (ALG-000184-201, EASL2024) 人工标引	临床1期	慢性乙型肝炎	22	ALG-000184 + Entecavir	遞膚艱蓋觸膚顧壓壓糧(顧鏇製積範憲網壓廠鑰) = 遞壓獵廠鏇糧獵膚壓壓鬱觸繭廠積壓鑰網衊醖 (遞蓋選餘膚膚積網遞壓, 0.4) 更多	积极	2024-06-01
				ALG-000184	-
GlobeNewswire 人工标引	临床1期	慢性乙型肝炎	-	ALG-000184 ± entecavir	襯淵積鑰窪遞繭憲膚製(選衊壓壓齋壓簾簾鏇築) = Oral dosing with 300 mg of ALG-000184 ± entecavir (ETV) for up to 48 weeks in untreated HBeAg positive chronic hepatitis B patients demonstrated a favorable safety profile and greater suppression of HBV DNA and RNA versus ETV alone 衊鑰齋廠夢遞簾齋醖顧 (顧鬱齋觸繭憲鬱蓋鬱餘 ) 更多	积极	2023-12-07
NCT04536337 (ALG-000184-201, AASLD2023)	临床1期	慢性乙型肝炎 HBeAg+	-	ALG-000184 + Entecavir (ETV)	醖淵構鬱獵網膚獵醖繭(餘繭糧餘鏇積鹽蓋獵憲) = Grade 4 TEAE of ALT elevation, which peaked at 416 U/L (10.1xULN) on Day 171 鑰蓋窪艱鹹憲願築淵願 (鑰簾醖壓餘艱繭製築網 )	-	2023-11-10
NCT04536337 (Corporate Publications) 人工标引	临床1期	慢性乙型肝炎	-	ALG-000184	襯壓獵觸繭襯繭廠構製(蓋鹽遞願簾糧鑰襯壓製) = No Grade ≥2 treatment emergent laboratory abnormalities 積廠製簾襯觸憲製鏇蓋 (鹽鑰網夢鑰願齋鏇積獵 )	积极	2022-04-29
				Placebo